Table 3.

Visual acuity, central macular thickness, and fluorescein angiography score before and after tocilizumab therapy in seven patients with non-infectious uveitis.

			VA (ETDRS)			AC Cells (0–4)			AC Flare (0–4)			VH (0–4)			CST (μm)		FA Score
Pt no	Eye	Int	3rd cycle	Fnl	Int	3rd cycle	Fnl	Int	3rd cycle	Fnl	Int	3rd cycle	Fnl	Int	3rd cycle	Fnl	Int	3rd cycle	Fnl
1	OD	65	80	80	0	0	0	2	0.5	0.5	0.5	0	0	514	289	283	16	0	0
2	OD	35	35	35	0	0	0	2	1	1	2	1	0.5	334	N/A	333	12	5	3
3	OS	70	80°	80	1	0°	0	2	1°	1	1*	1°,*	1*	N/A	321°	321	N/A	5°	3
4	OD	25	25	25	0	0	0	2	1	1	0.5	0	0	328	N/A	315	17	6	4
5	OD	85	85°	85	0	0°	0	1	0.5°	0.5	0.5	0°	0	N/A	263°	247	14	5°	3
5	OS	75	75°	80	0	0°	0	0.5	0.5°	0.5	0.5	0.5°	0.5	N/A	273°	259	14	12°	9
6	OD	25	35	35	0	0	0	1	1	1	1*	1*	1*	296	276	264	13	6	2
6	OS	70	70	70	0	0	0	1	0.5	0.5	0	0	0	293	285	267	6	2	3
7	OD	55	55	55	1	0	0	1	0.5	0.5	0.5	0.5	0.5	524	378	373	16	8	7
7	OS	85	85	85	2	0	0	2	0.5	0.5	0	0	0	322	319	320	5	2	2

Pt: patient, TCZ: tocilizumab, VA: visual acuity, CST: central subfield thickness, FA: fluorescein angiography, Int: initial, Fnl: final.

^°After 3 cycles of 4 mg TCZ infusions.

^*Presence of cataract.